Royal Bank Of Canada reiterated their outperform rating on shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) in a research note issued to investors on Wednesday.

A number of other research firms have also recently weighed in on ICPT. Laidlaw reissued a hold rating and issued a $119.00 target price (up previously from $115.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, August 1st. Cowen and Company reissued an outperform rating and issued a $232.00 target price on shares of Intercept Pharmaceuticals in a research note on Thursday, September 14th. BMO Capital Markets upped their target price on shares of Intercept Pharmaceuticals from $218.00 to $221.00 and gave the company an outperform rating in a research note on Tuesday, August 1st. BidaskClub raised shares of Intercept Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, August 24th. Finally, Cantor Fitzgerald reissued an underweight rating and issued a $69.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Intercept Pharmaceuticals has a consensus rating of Hold and an average target price of $162.88.

Shares of Intercept Pharmaceuticals (ICPT) traded up 5.86% during trading on Wednesday, reaching $72.76. The company’s stock had a trading volume of 3,178,144 shares. Intercept Pharmaceuticals has a 1-year low of $54.98 and a 1-year high of $156.65. The company’s 50-day moving average price is $94.11 and its 200 day moving average price is $111.08. The stock’s market capitalization is $1.83 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million for the quarter, compared to analysts’ expectations of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The firm’s revenue for the quarter was up 459.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($3.14) earnings per share. Analysts anticipate that Intercept Pharmaceuticals will post ($13.98) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/05/intercept-pharmaceuticals-inc-icpt-given-outperform-rating-at-royal-bank-of-canada.html.

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 1,532 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $58.87, for a total value of $90,188.84. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CMO David Shapiro sold 553 shares of the stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $124.01, for a total transaction of $68,577.53. Following the completion of the sale, the chief marketing officer now owns 44,562 shares in the company, valued at $5,526,133.62. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,920 shares of company stock worth $672,822. Company insiders own 9.20% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of ICPT. Sphera Funds Management LTD. increased its position in shares of Intercept Pharmaceuticals by 100.0% during the second quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock worth $3,632,000 after acquiring an additional 15,000 shares in the last quarter. Oppenheimer & Co. Inc. increased its position in shares of Intercept Pharmaceuticals by 9.0% during the first quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 178 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Intercept Pharmaceuticals by 12.8% during the first quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock worth $16,301,000 after acquiring an additional 16,392 shares in the last quarter. Van ECK Associates Corp increased its position in shares of Intercept Pharmaceuticals by 9.2% during the first quarter. Van ECK Associates Corp now owns 25,550 shares of the biopharmaceutical company’s stock worth $2,890,000 after acquiring an additional 2,161 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Intercept Pharmaceuticals by 10.2% during the first quarter. Bank of New York Mellon Corp now owns 68,302 shares of the biopharmaceutical company’s stock worth $7,725,000 after acquiring an additional 6,312 shares in the last quarter. Institutional investors own 82.19% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.